Dr. Kenneth Shain, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of South Florida

  Residency Hospital

• Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma, 2015-07-15

• XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of I?Ba and overcomes acquired proteasome inhibitor resistance in human multiple myeloma, 2016-10-28

• Evaluating Kinase ATP Uptake and Tyrosine Phosphorylation using Multiplexed Quantification of Chemically Labeled and Post-Translationally Modified Peptides, 2015-03-14

• Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma, 2019-06-17

• Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma, 2023-06-20

• MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas, 2021-01-14

• Proteometabolomics of Melphalan Resistance in Multiple Myeloma, 2020-12-18

• Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors, 2016-08-24

• Lenalidomide-based response-adapted therapy for older adults without high risk myeloma, 2018-12-12

• Multiple Myeloma DREAM Challenge reveals epigenetic regulatorPHF19as marker of aggressive disease, 2020-02-14

• BCL2Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models, 2019-05-13

• Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide, 2016-04-20

• Unification ofde novoand acquired ibrutinib resistance in mantle cell lymphoma, 2017-04-18

• A Phase 1/2 Study of evofosfamide, A Hypoxia-Activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma, 2018-10-02

• Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment, 2016-02-22

• Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma, 2021-03-16

• Oprozomib in patients with newly diagnosed multiple myeloma, 2019-08-16

• Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma, 2009-12-15

• Replicative Instability Drives Cancer Progression, 2022-10-26

• Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma, 2021-05-28

• Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel, 2023-09-25

• An ex vivo platform for the prediction of clinical response in multiple myeloma, 2017-04-11

• Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide, 2016-07-18